O1-8-3Phase II study of erlotinib + onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
Sakai, Hiroshi, Kishi, Kazuma, Seto, Takashi, Kozuki, Toshiyuki, Nishio, Makoto, Imamura, Fumio, Nokihara, Hiroshi, Satouchi, Miyako, Tahata, Takashi, Nakagawa, KazuhikoVolume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv471.14
Date:
November, 2015
File:
PDF, 34 KB
english, 2015